Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia
- 1 January 2002
- Vol. 59 (1) , 63-67
- https://doi.org/10.1016/s0090-4295(01)01454-6
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- Pfizer (U01DK46418, U01DK49971, U01DK49977, U01DK49963, U01DK49960, U01DK49964, U01DK46468, U01DK46472, U01DK49961, U01DK49921, U01DK49951, U01DK49980, U01DK49880, U01DK46437, U01DK46416, U01DK49954, U01DK49912, U01DK46429)
- Merck
This publication has 21 references indexed in Scilit:
- A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 1998
- EPIDEMIOLOGIC TRENDS IN THE EVALUATION AND TREATMENT OF LOWER URINARY TRACT SYMPTOMS IN ELDERLY MALE MEDICARE PATIENTS FROM 1991 TO 1995Journal of Urology, 1998
- Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic HyperplasiaUrology, 1998
- Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter StudyUrology, 1998
- Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic HyperplasiaEuropean Urology, 1998
- Recruitment in the Trial of Nonpharmacologic Intervention in the Elderly (TONE)Journal of the American Geriatrics Society, 1997
- The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic HyperplasiaNew England Journal of Medicine, 1996
- A multicenter, randomized, double-blind, placebocontrolled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasiaUrology, 1996
- Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled studyUrology, 1995
- The Effect of Finasteride in Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1992